Is there a connection between immunohistochemical markers and grading of lung cancer with apparent diffusion coefficient (ADC) and standardised uptake values (SUV) of hybrid 18F-FDG-PET/MRI?
magnetic resonance imaging
nuclear imaging
Journal
Journal of medical imaging and radiation oncology
ISSN: 1754-9485
Titre abrégé: J Med Imaging Radiat Oncol
Pays: Australia
ID NLM: 101469340
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
11
03
2020
revised:
21
06
2020
accepted:
28
06
2020
pubmed:
25
7
2020
medline:
10
11
2021
entrez:
25
7
2020
Statut:
ppublish
Résumé
To correlate tumour grading and prognostic immunohistochemical markers of lung cancer with simultaneously acquired standardised uptake values (SUV) and apparent diffusion coefficient (ADC) derived from hybrid PET/MRI. In this retrospective study, 55 consecutive patients (mean age 62.5 ± 9.2 years) with therapy-naïve, histologically proven lung cancer were included. All patients underwent whole-body PET/MRI using 18F-flourdeoxyglucose (18F-FDG) as a radiotracer. Diffusion-weighted imaging of the chest (DWI, b-values: 0, 500, 1000 s/mm The average SUVmax, SUVmean, ADCmin and ADCmean in lung cancer primaries were 12.6 ± 5.9, 7.7 ± 4.6, 569.9 ± 96.1 s/mm 18F-FDG-PET/MRI showed weak to moderate correlations between SUV, ADC, tumour grading and erbB2-expression of lung cancer. Hence, 18F-FDG-PET/MRI may, to some extent, offer complementary information to the histopathology of lung cancer, for the evaluation of tumour aggressiveness and treatment response.
Identifiants
pubmed: 32705779
doi: 10.1111/1754-9485.13087
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
779-786Informations de copyright
© 2020 The Royal Australian and New Zealand College of Radiologists.
Références
Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol 2016; 893: 1-19.
Goldstraw P, Ball D, Jett JR et al. Non-small-cell lung cancer. Lancet 2011; 378: 1727-40.
Antoch G, Stattaus J, Nemat AT et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 2003; 229: 526-33.
Goeckenjan G, Sitter H, Thomas M et al. Prevention, diagnosis, therapy, and follow-up of lung cancer: interdisciplinary guideline of the German Respiratory Society and the German Cancer Society. Pneumologie 2011; 65: 39-59.
Ohno Y, Yoshikawa T, Kishida Y et al. Diagnostic performance of different imaging modalities in the assessment of distant metastasis and local recurrence of tumor in patients with non-small cell lung cancer. J Magn Reson Imaging 2017; 46: 1707-17.
Schaarschmidt BM et al. Thoracic staging with (18)F-FDG PET/MR in non-small cell lung cancer - does it change therapeutic decisions in comparison to (18)F-FDG PET/CT? Eur Radiol 2017; 27: 681-8.
Heusch P, Buchbender C, Kohler J et al. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT. J Nucl Med 2014; 55: 373-8.
Schwenzer NF, Schraml C, Müller M et al. Pulmonary lesion assessment: comparison of whole-body hybrid MR/PET and PET/CT imaging-pilot study. Radiology 2012; 264: 551-8.
Cerfolio RJ, Bryant AS, Ohja B et al. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg 2005; 130: 151-9.
Lee DW, Chong GO, Lee YH et al. Role of SUVmax and GLUT-1 expression in determining tumor aggressiveness in patients with clinical stage I endometrioid endometrial cancer. Int J Gynecol Cancer 2015; 25: 843-9.
Janvier L, Olivier P, Blonski M et al. Correlation of SUV-derived indices with tumoral aggressiveness of gliomas in static 18F-FDOPA PET: use in clinical practice. Clin Nucl Med 2015; 40: e429-35.
Razek AA. Diffusion magnetic resonance imaging of chest tumors. Cancer Imaging 2012; 12: 452-63.
Buchbender C, Heusner TA, Lauenstein TC, Bockisch A, Antoch G. Oncologic PET/MRI, part 2: bone tumors, soft-tissue tumors, melanoma, and lymphoma. J Nucl Med 2012; 53: 1244-52.
Chen L, Liu M, Bao J et al. The correlation between apparent diffusion coefficient and tumor cellularity in patients: a meta-analysis. PLoS One 2013; 8: e79008.
Kim JK, Kim KA, Park B-W, Kim N, Cho K-S. Feasibility of diffusion-weighted imaging in the differentiation of metastatic from nonmetastatic lymph nodes: early experience. J Magn Reson Imaging 2008; 28: 714-9.
Ohno Y, Koyama H, Yoshikawa T et al. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy. AJR 2012; 198: 75-82.
Bohle RM, Schnabel PA. Grading of lung cancer. Pathologe 2016; 37: 314-9.
Phernambucq EC, Hartemink KJ, Smit EF et al. Tumor cavitation in patients with stage III non-small-cell lung cancer undergoing concurrent chemoradiotherapy: incidence and outcomes. J Thorac Oncol 2012; 7: 1271-5.
Song PJ et al. Comparison of effects of 18F-FDG PET-CT and MRI in identifying and grading gliomas. J Biol Regul Homeost Agents 2016; 30: 833-8.
Zhao SJ et al. Primary tumor SUVmax measured on (18)F-FDG PET-CT correlates with histologic grade and pathologic stage in non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 2013; 35: 754-7.
Zhan C et al. Identification of immunohistochemical markers for distinguishing lung adenocarcinoma from squamous cell carcinoma. J Thorac Dis 2015; 7: 1398-405.
Lin G, Doyle LA. An update on the application of newly described immunohistochemical markers in soft tissue pathology. Arch Pathol Lab Med 2015; 139: 106-21.
Catalano OA, Horn GL, Signore A et al. PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype. Br J Cancer 2017; 116: 893-902.
Heusch P, Buchbender C, Köhler J et al. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results. Rofo 2013; 185: 1056-62.
Regier M et al. Diffusion weighted MRI and 18F-FDG PET/CT in non-small cell lung cancer (NSCLC): does the apparent diffusion coefficient (ADC) correlate with tracer uptake (SUV)? Eur J Radiol 2012; 81: 2913-8.
Travis WD, Brambilla E, Nicholson AG et al. The 2015 World Health Organization Classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 2015; 10: 1243-60.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-72.
Huang W, Zhou T, Ma L et al. Standard uptake value and metabolic tumor volume of (1)(8)F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2011; 38: 1628-35.
Matoba M, Tonami H, Kondou T et al. Lung carcinoma: diffusion-weighted mr imaging-preliminary evaluation with apparent diffusion coefficient. Radiology 2007; 243: 570-7.
Weber WA, Petersen V, Schmidt B et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003; 21: 2651-7.
Gu J, Khong P-L, Wang S, Chan Q, Law W, Zhang J. Quantitative assessment of diffusion-weighted MR imaging in patients with primary rectal cancer: correlation with FDG-PET/CT. Mol Imaging Biol 2011; 13: 1020-8.
Wong CS, Gong N, Chu Y-C et al. Correlation of measurements from diffusion weighted MR imaging and FDG PET/CT in GIST patients: ADC versus SUV. Eur J Radiol 2012; 81: 2122-6.
Sasaki M, Tozaki M, Kubota K et al. Simultaneous whole-body and breast 18F-FDG PET/MRI examinations in patients with breast cancer: a comparison of apparent diffusion coefficients and maximum standardized uptake values. Jpn J Radiol 2018; 36: 122-33.
Deng S et al. Meta-analysis of the correlation between apparent diffusion coefficient and standardized uptake value in malignant disease. Contrast Media Mol Imaging 2017; 2017: 4729547.
Padhani AR, Liu G, Mu-Koh D et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009; 11: 102-25.
Kralik SF, Taha A, Kamer AP, Cardinal JS, Seltman TA, Ho CY. Diffusion imaging for tumor grading of supratentorial brain tumors in the first year of life. AJNR 2014; 35: 815-23.